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See Editorial, pages 532–534Background & Aims: Non-selective beta blockers (NSBBs) have dosage was specifically recorded. Patient characteristics at enroll-
been shown to have deleterious outcomes in patients with refrac- ment significantly associated with treatment and mortality were
tory ascites, alcoholic hepatitis and spontaneous bacterial peri-
tonitis leading many physicians to stop the drug in these cases.
Acute-on-chronic liver failure (ACLF) is characterized by systemic
inflammation and high mortality. As NSBBs may have beneficial
effects on gut motility and permeability and, systemic inflamma-
tion, the aims of this prospective, observational study were to
determine whether ongoing use of NSBBs reduced 28-day mor-
tality in ACLF patients.
Methods: The study was performed in 349 patients with ACLF
included in the CANONIC study, which is a prospective observa-
tional investigation in hospitalized cirrhotic patients with acute
deterioration. The data about the use of NSBBs, its type andJournal of Hepatology 20
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ment effect. A logistic regression model was fitted.
Results: 164 (47%) ACLF patients received NSBBs whereas 185
patients did not. Although the CLIF-C ACLF scores were similar
at presentation, more patients in the NSBB treated group had
lower grades of ACLF (p = 0.047) at presentation and significantly
more patients improved. Forty patients (24.4%) died in NSBB trea-
ted group compared with 63 patients (34.1%) (p = 0.048) [esti-
mated risk-reduction 0.596 (95%CI: 0.361–0.985; p = 0.0436)].
This improvement in survival was associated with a significantly
lower white cell count (NSBB: 8.5 (5.8); no NSBB: 10.8 (6.6);
p = 0.002). No long-term improvement in survival was observed.
Conclusions: This study shows for the first time that ongoing
treatment with NSBBs in cirrhosis is safe and reduces the mortal-
ity if they develop ACLF. Careful thought should be given before
stopping NSBBs in cirrhotic patients.
 2015 European Association for the Study of the Liver. Published
by Elsevier B.V. All rights reserved.Introduction
Acute-on-chronic liver failure (ACLF) is a recently defined entity
characterized by acute deterioration of liver function, multi-
organ failure and high mortality [1–4]. A characteristic feature
of this syndrome is systemic inflammation, the severity of which
is an independent predictor of mortality [4,5]. The mechanism(s)
underlying this severe systemic inflammation is unknown. The
use of classical anti-inflammatory agents, such as anti-tumour16 vol. 64 j 574–582
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necrosis factor or steroids in ACLF is fraught with potential
difficulties as infection and immune failure are also important
features of this syndrome and when present, is associated with
a high risk of mortality [2,5–7]. Treatment of ACLF is an unmet
need and modulation of inflammatory response in ACLF is an
important potential target of therapy [8].
Recently, much controversy has arisen in the literature due to
the suggestion that the use of non-selective beta blockers
(NSBBs) in patients with refractory ascites [9,10], spontaneous
bacterial peritonitis [11] and alcoholic hepatitis [12], may
increase mortality rates through accentuation of circulatory
disturbances and the resultant renal failure. These studies are
limited in their design as they address specific subgroups of
patients such as refractory ascites and spontaneous bacterial
peritonitis and lack prospective data assessing extrahepatic,
extrarenal organ functions as well as overall severity using prog-
nostic scores other than liver-specific scores. Despite these limi-
tations, many clinicians are ceasing to use this potentially
lifesaving drug in patients with advanced cirrhosis despite
another study suggesting improved outcomes for patients on
the waiting list for liver transplantation [13].
NSBBs have been studied extensively in cirrhotic patients and
are the drug of first choice for primary and secondary prophylaxis







Age (yr) 53.6 (11.5) 58.1 (11.8) 0.0003
Male sex 117 (63.2%) 111 (67.7%) 0.3844
Cause of cirrhosis:
Alcohol alone 113 (62.4%) 85 (54.1%) 0.1228
HCV alone 22 (12.2%) 26 (16.6%) 0.2471
HCV + alcohol 20 (11.1%) 11 (7.0%) 0.1990
Previous decompensations 116 (65.5%) 137 (86.7%) <0.0001
 Ascites 102 (87.9%) 118 (86.8%) 0.7817
 Hepatic encephalopathy 56 (49.1%) 66 (49.6%) 0.9374
 Gastrointestinal bleeding 19 (16.8%) 58 (43.3%) <0.0001
 Spontaneous bacterial peritonitis 19 (17.3%) 20 (15.5%) 0.7122
 Other 23 (20.7%) 26 (19.9%) 0.8662
Potential precipitating events of ACLF:
  At least one PE 110 (62.2%) 95 (59.8%) 0.6527
  >1 PE 41 (23.2%) 26 (16.4%) 0.1187
  Bacterial infection 57 (30.8%) 53 (32.3%) 0.7624
  Gastrointestinal hemorrhage 31 (16.8%) 22 (13.4%) 0.3852
Active alcoholism before 
admission
50 (28.9%) 28 (18.1%) 0.0214
  Other PEs 13 (7.3%) 13 (8.3%) 0.7388
Ascites clinically diagnosed 149 (81.0%) 119 (73.0%) 0.0771
Ascites + subrogates of ascites 177 (95.7%) 158 (96.3%) 0.7517
Mean arterial pressure (mmHg) 78.9 (12.7) 78.2 (13.3) 0.6639
Heart rate (bpm) 89.8 (19.0) 79.0 (19.5) <0.0001
Organ failures:
  Liver 80 (43.2%) 57 (34.8%) 0.1051
  Kidney 89 (48.1%) 89 (54.3%) 0.2506
  Cerebral 51 (27.6%) 30 (18.3%) 0.0405
Data are n (%), mean (standard deviation) or median (Inter-quartile range).
NSBBs, non-selective beta blockers.
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[14]. These effects require both the beta-1 and beta-2 actions of
the drug to ameliorate splanchnic vasodilation and high cardiac
output [15]. NSBBs have many other potential beneficial actions
in patients with cirrhosis through its action on increasing gut
motility and reducing bacterial translocation, which would
reduce systemic inflammation and therefore have beneficial
effects in ACLF patients over and above its hemodynamic effects
[16,17].
This study was designed to test the hypothesis that cirrhotic
patients being treated with NSBBs would have reduced sys-
temic inflammation and reduced mortality if they developed
ACLF. In order to test this, we used the data from the CANONIC
study, which is a prospective, observational study performed in
1349 cirrhotic patients included from 29 European hospitals
[2]. The present analysis is focused on the ACLF cohort. The
data from this study was previously used to derive the diag-
nostic and prognostic criteria for ACLF, which were validated
in independent cohorts [2–4]. The specific aims of this study
were to evaluate the clinical effects of ongoing administration
of NSBBs in hospitalized cirrhotic patients who developed ACLF,
focusing on safety of its use, effects on organ function and
mortality, clinical course of ACLF and effects on inflammatory
markers.BBs within the previous 3 months.
 Coagulation 66 (35.7%) 42 (25.6%) 0.0423
 Circulation 35 (18.9%) 27 (16.5%) 0.5492
 Lungs 19 (10.3%) 19 (11.6%) 0.6938
Kidney dysfunction 35 (22.2%) 19 (13.8%) 0.0624
 Mild to moderate hepatic 
encephalopathy
54 (34.2%) 51 (37.0%) 0.6281
CLIF-C  ACLF score 51.4 (10.2) 49.5 (10.0) 0.1468
MELD score 28.9 (7.4) 27.1 (7.6) 0.0546
Laboratory data:
  Hematocrit (%) 27 (5) 27 (5) 0.6888
  Platelet count (x109/L) 97 (77) 81 (60) 0.0492
  Serum bilirubin (mg/dl) 13.8 (11.9) 10.1 (11.0) 0.0072
  International normalized ratio 2.3 (1.0) 2.2 (1.0) 0.3580
  Alanine aminotransferase (U/L) 35 (22-66) 34 (21-66) 0.5149
  Aspartate aminotransferase (U/L) 77 (41-143) 68 (35-123) 0.4698
  γ-Glutamyltransferase (U/L) 77 (30-151) 70 (36-138) 0.6451
  Serum creatinine (mg/dl) 2.0 (1.4) 2.1 (1.3) 0.4328
  Serum sodium (mmol/L) 134.3 (6.7) 136.0 (6.1) 0.0199
  WBC (x109/L) 10.8 (6.6) 8.5 (5.8) 0.0021
  Plasma C-reactive protein (mg/L) 33.5 (16-54) 25.4 (13-52) 0.4664
ACLF grade:
  ACLF-1 81 (43.8%) 91 (55.5%)
  ACLF-2 73 (39.5%) 57 (34.8%)
  ACLF-3 31 (16.7%) 16 (9.7%) 0.0474
Liver transplantation after 28 days 15 (8.1%) 17 (10.4%) 0.2009
Liver transplantation after 90 days 24 (13.1%) 26 (16.2) 0.4660
28-day mortality 63 (34.1%) 40 (24.4%) 0.0482











The study was performed in 349 patients with ACLF and complete set of data
included in the CANONIC study, which is a prospective observational investiga-
tion in 1349 patients with cirrhosis (out of 2149 screened) who were admitted
to 29-European hospitals within a period of 6 months for the treatment of an
acute decompensation (AD) (ascites, encephalopathy, gastrointestinal hemor-
rhage and/or bacterial infections) [2]. Among the causes of exclusion the most fre-
quent were: hospitalization for a scheduled diagnostic or therapeutic procedure,
hepatocellular carcinoma outside the Milan Criteria, patient’s refusal to partici-
pate and presence of severe chronic extrahepatic disease. Two hundred and
seventy-seven patients presented with ACLF at study enrollment and 72
(20.6%) developed ACLF during hospitalization.
Data collection
Data from history, including events that may be potential precipitating factors of
ACLF, physical examination and laboratory measurements were obtained at ACLF
diagnosis in all patients as described previously [2]. Special attention was given to
data from the previous 3-months up to ACLF development, including alcohol
drinking habit of the patients, therapeutic procedures (paracentesis with and
without albumin, transjugular intrahepatic portosystemic shunting, major sur-
gery) and pharmacological treatments (primary or secondary prophylaxis of bac-
terial infections and gastrointestinal hemorrhage with norfloxacin, secondary
prophylaxis of hepatic encephalopathy with lactulose or rifaximin and treatment
with diuretics or antibiotics). Following diagnosis of ACLF, an intensive pre-
specified 28-day follow-up data collection was performed in all patients. Finally,
as pre-specified in the study protocol, information on liver transplantation, mor-
tality and causes of death during 1-year were obtained for all study patients. Data
were collected using an electronic case report-form. The main end-point for the
present study focused on 28-day survival.
Data about use of NSBBs
The data about the use of NSBBs, its type and dosage was specifically recorded in
the case notes. If the patients were not receiving NSBBs at the time of hospital
admission, a specific note about when they were started on therapy was noted.
Diagnostic criteria
Diagnostic criteria of organ failure were based on the CLIF-C organ failure score
[4]: Liver Failure: serum bilirubin P12 mg/dl; Renal failure: serum creatinine
P2 mg/dl; Cerebral failure: grade III-IV hepatic encephalopathy (West-Haven
classification); Coagulation failure: international normalized ratio (INR) P2.5;
Circulatory failure: use of vasoconstrictors to treat severe arterial hypotension
(use of vasoconstriction for the treatment of type 1 HRS in patients without sev-
ere hypotension not included); Respiratory failure: PaO2/FiO2 P200 or SpO2/FiO2
P214. Renal dysfunction was diagnosed when serum creatinine ranged between
1.5 and 1.9 mg/dl; cerebral dysfunction was diagnosed in patients with Grade I or
Grade II hepatic encephalopathy. Type 1 ACLF defines the presence of renal failure
alone or of any other type of single renal failure if associated to renal dysfunction
and/or cerebral dysfunction. Type II ACLF and type III ACLF define the presence of
2 and 3 to 6 organ failures, respectively.
Statistical analysis
Data were summarized by means of the appropriate descriptive statistics: means
and Standard Deviation (SD) or median and Inter-quartile range (IQR) values for
continuous variables, frequencies and percentages for categorical parameters.
Univariate analyses of the effect of the treatment with NSBBs included student’s
t test or Mann-Whitney U test for parametric or non-parametric pair-wise com-
parisons, respectively, and Chi-square tests for categorical variables. Survival
curves were estimated by means of Kaplan-Meier method and compared using
the log-rank test.
The main study objective was that of assessing the effects of the administra-
tion of NSBBs on 28-day mortality in ACLF patients. Patients’ characteristics prior
to ACLF onset (corresponding to study inclusion for most patients) significantly
associated with both the treatment and mortality were taken into account as
potential confounders to adjust treatment effects. A logistic regression model576 Journal of Hepatology 201was fitted to adjust the effect of NSBBs for the potential confounders, which were
kept in the final model only if they led at least to a 10% change in the model coef-
ficient estimated for the use of NSBBs. A logistic regression model was also fitted
to estimate the probability of death at 28 days in patients taking or not taking
NSBBs at different levels of severity of the patients, as measured by the CLIF-C
ACLF score. In all statistical comparisons, a 0.05 significance level (two-tailed)
was assumed.Results
Differences in clinical and laboratory characteristics between
patients with ACLF who did and did not received NSBBs prior to
enrollment
Of the 349 patients with valid data on NSBB use and developing
ACLF at enrollment or during the hospitalization, 164 (47%)
received NSBBs. Of these, 9 patients were started on therapy with
NSBBs after hospital admission whereas 155 received NSBB
within 3 months prior to ACLF diagnosis. One hundred and
eighty-five patients did not receive NSBBs. Similar numbers of
patients in the two groups received antibiotics within 3-months
of hospital admission (NSBB: 45.7%; No NSBB: 41.6%; p = 0.43).
One hundred and eleven patients (67.7%) received propranolol
at a median dose of 40 mg (20–80) per day, 6 patients were
taking nadolol (3.7%; 40 mg (40–80)), 16 were taking carvedilol
(10%; 12.5 mg (6.25–25)) and 31 were taking ‘other’ NSBBs
(18.9%; 40 mg (25–80)). Table 1 shows the clinical, laboratory,
liver transplantation and mortality data in these patients. There
were no significant differences between patient characteristics
dependent on when the NSBBs were started (Supplementary
Table 1). Also, neither the type of NSBB administered nor its dose
of NSBBs was associated with mortality or effect on heart rate
and white cell count (Supplementary Tables 2 and 3). Therefore,
further analyses were performed to determine the differences
between NSBB administered group (n = 164) vs. those not admin-
istered NSBBs (n = 185).
Of the patients in the NSBB administered group, 77 patients
continued NSBBs following the diagnosis of ACLF, but the dose
was reduced in 8 patients. In 78 patients, the NSBBs were stopped
prior to inclusion in the study. In 68 of the 78 patients who dis-
continued NSBB after study enrollment (87%) ACLF was diag-
nosed at study inclusion. The rate of ACLF development after
study inclusion was similar in both groups (13% in patients dis-
continuing the treatment vs. 17% in patients continuing with
NSBB) (Supplementary Table 4).
Patients receiving NSBBs were significantly older and had sig-
nificantly higher prevalence of prior episodes of previous decom-
pensation than patients not receiving NSBBs. This latter finding
was due to a significantly higher prevalence of prior episodes of
gastrointestinal hemorrhage in patients receiving NSBBs. The
remaining previous decompensating events were similar in the
two groups. There were no differences between groups in the eti-
ology of cirrhosis, number of patients with precipitating events
and its type except for active alcoholism within the 3-months
prior to hospitalization, which was significantly more prevalent
in patients not receiving NSBBs. There was also no difference
between groups in relation to the prevalence of ascites, either
as assessed by the presence of clinically detectable ascites at ACLF
diagnosis or by the sum of clinically detectable ascites at enroll-
ment and surrogates of ascites (treatment with diuretics or para-
centesis or spontaneous bacterial peritonitis) within 1-week prior






















Patients with beta blockers
Patients w/out beta blockersp = 0.0032
p = 0.0427
Fig. 1. Evolution of the ACLF grade one week after diagnosis by use of non-
selective beta blockers.
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As expected, heart rate was significantly lower in patients
receiving NSBBs. This was associated with a higher serum sodium
concentration and, white cell count and bilirubin were signifi-
cantly lower in patients receiving NSBBs. MELD score was lower
in the patients treated with NSBBs which did not reach statistical
significance (28.9 (7.4) vs. 27.1 (7.6); p = 0.056). There were no
significant differences between groups in mean arterial pressure,
hematocrit, serum creatinine and plasma C-reactive protein.
Organ failures, prognostic scores and ACLF grades at diagnosis and
course of ACLF during 3–7 days after diagnosis
The prevalence of cerebral failure and coagulation failure was sig-
nificantly lower in patients receiving NSBBs. The prevalence of
other organ failures between groups was not significantly differ-
ent. There were no significant differences in cerebral dysfunction
but renal dysfunction was lower in the patients treated with
NSBBs (p = 0.06). Creatinine levels at last study visit were similar
between study groups. (NSBB: 1.79 mg/dl (1.39); No NSBB:
1.73 mg/dl (1.12). p = 0.67). The CLIF-C ACLF scores were similar
between the groups (Table 1). There were, however significant
differences in the severity of ACLF. The prevalence of ACLF-1
was higher in patients receiving NSBBs. In contrast, the preva-
lence of ACLF-2 and ACLF-3 was higher in patients not receiving
NSBBs.
The early clinical course of ACLF was significantly worse in
patients not receiving NSBBs. The evolution of ACLF grade after
3–7 days from the diagnosis in the 319 patients with complete
data is shown in Table 2. Among patients not taking NSBBs, 40
(23.4%) presented a clinical course to more severe grade of the
syndrome, in comparison with 21 patients (14.2%) in the NSBB-
treatment group (p = 0.0371). This suggests a possible protective
effect of the treatment with NSBBs against the progression of the
syndrome (Relative Risk: 0.61; 95%CI: 0.38–0.98). Moreover, the
number of patients presenting a complete resolution of the initial
ACLF was higher in the NSBB treated group compared with the
untreated patients (46.6% vs. 37.4%), although in this case statis-
tical significance was not reached (p = 0.0967). Fig. 1 shows the
improvement or worsening in ACLF severity observed after
3–7 days from diagnosis. Significantly, more patients in the NSBB
treated group presented a 1-grade reduction in ACLF classifica-
tion (43.2% vs. 27.5%, p = 0.0032), while 1-grade worsening was
significantly higher in patients not treated with NSBBs (18.1%
vs. 10.1%, p = 0.0427).Table 2. Evolution of ACLF grade up to one week after its first onset according to tr
ACLF grade at the 
1st onset
ACLF grade after 3-7 days from the onset
No NSBBs (n = 171)
NO ACLF ACLF-1 ACLF-2 ACLF-3
ACLF-1 (n = 76) 36 (47.4%) 19 (25.0%) 12 (15.8%) 9  (11.8%)
ACLF-2 (n = 68) 24 (35.3%) 7 (10.3%) 18 (26.5%) 19 (27.9%)
ACLF-3 (n = 27) 4 (14.8%) 2 (7.4%) 4 (14.8%) 17 (63.0%)
Evolution of the initial ACLF grade
Resolution of the ACLF 64/171 (37.4%)
Worsening of the ACLF 40/171 (23.4%)
NSBBs, non-selective beta blockers.
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Short-term (28-day) mortality rate (Table 1) was significantly
higher and the probability of survival (Fig. 2) significantly lower
in patients not receiving NSBBs. When the probability of death
for patients with and without NSBBs was estimated for the differ-
ent values of the CLIF-C ACLF score (Fig. 3), the curve obtained in
patients receiving NSBBs was significantly shifted to the right,
indicating that for identical values of the score mortality was
lower in treated patients. Six-month and 1-year mortality rates
were similar between the groups (NSBB: 47.6% and 51.8%; No
NSBB: 49.7% and 56.8%; p = 0.64 and 0.35 respectively).
Effect of the treatment with NSBBs on survival
Table 3 shows an analysis of potential risk factors of mortality in
the univariate analysis. A history of more than one precipitating
event, higher heart rate, higher prevalence of organ failure (sta-
tistically significant only for liver, cerebral and circulation fail-
ure), higher CLIF-C ACLF score and MELD score, higher serum
bilirubin, INR, aspartate aminotransferase, serum creatinine and
white cell count (WCC), higher grade of ACLF and no treatment
with NSBBs were significantly associated with short-termmortal-
ity rate.
None of the baseline patients’ characteristics (age, gender,
etiology of the cirrhosis, previous decompensations, events
potentially precipitating the ACLF or clinical assessments) were
found to be significantly associated with treatment with NSBBseatment with NSBBs.
ACLF grade at 
the 1st onset
ACLF grade after 3-7 days from the onset
Use of NSBBs (n = 148)
NO ACLF ACLF-1 ACLF-2 ACLF-3
ACLF-1 (n = 83) 53  (63.9%) 19 (22.9%) 5 (6.0%) 6  (7.2%)
ACLF-2 (n = 52) 15  (28.9%) 9  (17.3%) 18 (34.6%) 10 (19.2%)
ACLF-3 (n = 13) 1 (7.7%) 0 2 (15.4%) 10 (76.9%)
Resolution of the ACLF 69/148 (46.6%) p = 0.0967
Worsening of the ACLF 21/148 (14.2%) p = 0.0371
6 vol. 64 j 574–582 577





















Fig. 2. Kaplan-Meier survival curves at 28 days after diagnosis in ACLF
patients taking (green line) and not taking (red line) non-selective beta






























p value for beta blocker effect: 0.0324
Fig. 3. Estimated probability of death at 28 days from logistic regressionmodel
in ACLF patients with (green line) or without (red line) non-selective beta
blockers by CLIF-C ACLF score levels. (This figure appears in colour on the web.)
Research Articleand mortality (Tables 1 and 3). In order to adjust treatment
effects for the observed imbalances in the factors unrelated to
the severity of liver disease at hospital admission, a logistic
regression model for 28-day mortality was fitted including age,
presence of previous decompensations and active alcoholism
within the 3 months prior to hospitalization together with the
treatment. The adjusted protective effect of the treatment esti-
mated through this model was statistically significant. The esti-
mated risk-reduction (OR) associated to the use of NSBBs was
0.596 (95% CI: 0.361–0.985; p = 0.0436). One death at 28 days
could be prevented for every 11 0.097 (95% CI: 6–334) patients
that are treated with NSBBs. The main causes of death were sim-
ilar in both groups and due predominantly to progressive multi-
organ failure or septic shock (Supplementary Table 5).
28-day (37.2% vs. 13%; p <0.0005) and 3-month mortality (50%
vs. 14.7%; p <0.001) were significantly higher in the patients that
stopped NSBBs after development of ACLF compared with those
that continued to take NSBBs. Although the MELD scores in these
groups were similar, the patients that stopped NSBBs were more
likely to have circulatory and lung failure and higher CLIF-C ACLF
scores (51.6 (11.3) vs. 46.9 (8.2); p <0.02). Mean arterial pressure578 Journal of Hepatology 201was similar between the groups but the heart rate was lower in
the group that continued NSBBs. Inflammatory markers, WCC
and C-reactive protein (CRP) were similar (Supplementary
Table 4).Relationship between the use of NSBBs, white cell count and severity
of ACLF
Table 4 shows the relationship between the use of NSBBs, white
cell count and the severity of ACLF. For ACLF grades 1 and 2 at
presentation, the WCC was significantly lower in the patients
treated with NSBBs compared with the untreated patients but
the counts were similar in the ACLF grade 3 patients (Table 4A).
In the patients that worsened their ACLF grade, the WCC was also
significantly higher in the patients not being treated with NSBBs
compared with the patients treated with NSBBs (Table 4B).Discussion
The results of this study show for the first time that in patients
with cirrhosis presenting with ACLF, NSBBs were safe to adminis-
ter and its use was independently associated with improved
28-day survival. This reduction in short-term mortality with the
use of NSBBs was due to significantly greater number of patients
having lower grades of ACLF at presentation and, in those with
ACLF, resolving ACLF completely or to lower grades. This
reduction in 28-day mortality did not translate into improved
long-term mortality and this may be due to the relatively fewer
additional deaths at the 6-month and 1-year time points. The
mechanism of this improvement may be an NSBB-induced reduc-
tion in the severity of systemic inflammatory response indicated
by lower WCC and CRP both at the time of presentation and also
during hospital follow-up. The results suggest that ongoing treat-
ment with NSBBs in cirrhotic patients reduces the severity of sub-
sequent ACLF and prevents its progression to more advanced
stages, which together contributes to lower mortality.
Systemic inflammation, characterized by an increased WCC
and heart rate are the pathophysiological hallmarks of ACLF
[1,2,4,5,8]. As shown in previous studies, these markers were sig-
nificantly more elevated in the ACLF patients who died and the
WCC was an independent predictor of mortality [2,4]. The admin-
istration of NSBBs was associated with a significant reduction in
WCC, which was consistent with a reduction in the heart rate. As
illustrated in Table 4, in patients not treated with NSBBs, the WCC
was higher in the matched patients with ACLF grades 1 and 2. It is
notable that the WCC was also significantly higher in the patients
who progressed to the more advanced stages of the disease. The
exact mechanism of how this is achieved is not clear and may
indicate an effect on the sympathetic nervous system, which is
known to contribute to immune cell failure in sepsis [19–22].
This hypothesis will need to be explored in future studies. Addi-
tionally, NSBBs may reduce systemic inflammation through its
action on increasing gut motility and reducing bacterial translo-
cation [16,17], which is known to sensitize end organs to a
subsequent inflammatory injury [23]. This thinking is the
rationale behind the concept of gut sterilization using Nor-
floxacin and Rifaximin, which have been shown to reduce the
incidence of renal failure and hepatic encephalopathy in suscep-
tible patients [24,25]. In keeping with this hypothesis, a recent
meta-analysis showed that NSBBs reduced the risk of6 vol. 64 j 574–582
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development of spontaneous bacterial peritonitis (SBP) in suscep-
tible cirrhotic patients [26]. Alternatively, the observed effect of
NSBBs may represent a direct drug effect. Esmolol, a selective
beta-1 blocker was studied in patients with severe septic shock
(without underlying cirrhosis) and shown to be safe with poten-
tially beneficial effects on multi-organ function and inflammatory
markers [18]. Taken together, many interacting mechanisms
working through both the beta-1 and the beta-2 pathways may
be involved in the modulation of systemic inflammation
observed in the present study. Further studies will be needed to
look at the potential role of adrenoreceptors, severity of activa-
tion of the sympathetic nervous system and their role in modula-
tion of inflammatory responses.
NSBBs were first reported to have adverse survival outcomes
in patients with refractory ascites in retrospective studies [9].
The proposed mechanism underlying this increased mortality of
patients with refractory ascites was a greater incidence of post-
paracentesis circulatory dysfunction in the patients being treated
with NSBBs [10]. In the present study, similar numbers of
patients in either group had ‘severe ascites’ and renal failure.
Mean arterial pressure in the two cohorts was also similar at pre-
sentation. More recent studies evaluating larger numbers of
patients have not confirmed the observation of increased mortal-
ity in patients with refractory ascites [11,13]. In fact, in a multi-
center study in decompensated patients on the waiting list for
liver transplantation, administration of NSBBs was associated
with better survival [13]. Furthermore, in a recent systematic
review of 9 trials of NSBBs, 1 case-control study and 4 retrospec-
tive analyses, increased mortality was only observed in 1 study
described above [27]. In keeping with these latter studies, the
data from the present, study has not found any evidence that
patients with mild or severe ascites with or without its surro-
gates do any worse with NSBBs.
In the past 5-years or so, data from retrospective studies have
questioned the role of NSBBs in patients with SBP [11]. Bacterial
infection as a cause of acute decompensation in the present study
was similar in the patients treated with or without NSBBs, which
is in keeping with data from the US showing no differences in the
rates of infection in compensated or decompensated cirrhotic
patients [28]. Importantly, survival in the present study was
not related to the presence, type or site of infection. This observa-
tion is important given the recent debate about the use of NSBBs
in patients with SBP [11,13,16]. In a large single center retrospec-
tive study from Austria, which included 182 patients, the investi-
gators suggested that the administration of NSBBs to patients
with SBP is associated with greater risk of renal failure and death
[11]. In the SBP sub-cohort in the present study, there was no dif-
ference in the mortality of patients treated with NSBB and those
without. Serste et al. recently reported that the use of NSBBs were
associated with increased risk of acute kidney injury in patients
with alcoholic hepatitis, which was also not confirmed in the pre-
sent study [12]. These data argue strongly against stopping NSBBs
in patients with refractory ascites, SBP or alcoholic hepatitis
unless there are specific contraindications.
It is important to note that the dose of NSBBs used in the pre-
sent study, in most of the patients was 40 mg (20–80) propra-
nolol per day or equivalent, which is lower than in most of the
previous studies described above [9–12]. The effect of the NSBB
in ACLF seems to be class related as no differences in outcomes
were observed with propranolol or other NSBBs. A further analy-
sis of the patients receiving low doses, i.e. <40 mg compared withJournal of Hepatology 201those on doses of 40 mg or more did not show any significant dif-
ferences between the groups in terms of effect on inflammatory
response or mortality. Paradoxically, the mean arterial pressure
was higher in those treated with the higher dose but the heart
rates were similar indicating that these higher doses were not
deleterious if they did not adversely affect mean arterial pressure.
The exact mechanism underlying the beneficial effect of NSBBs at
this low dose is unclear and further studies will be required to
determine whether the non-hemodynamic beneficial effects of
NSBBs in advanced cirrhotic patients can be achieved at these
lower doses. Despite the occurrence of ACLF, about 50% patients
were continued on therapy with NSBBs, the dose of which was
reduced in a small proportion of patients (8 patients; 10.3%).
The 28-day and 90-day mortality of the patients who continued
on therapy with NSBBs was significantly lower than the patients
in whom NSBBs were withdrawn. This effect was independent of
any significant differences in the markers of systemic inflamma-
tion such as WCC or CRP. Although the heart rate was lower in
the patients who continued on therapy with NSBBs, mean arterial
pressure was similar. It is not possible to conclude that the
improved survival was due to a drug effect of continued NSBB
use as the patients in whom NSBBs were stopped had higher
number of patients with ACLF3, circulatory and lung failure
resulting in higher CLIF-C ACLF score. Specifically designed stud-
ies need to be performed to answer this question.
Patients on NSBBs tended to be older with a history of previ-
ous decompensation and were less likely to be alcoholics who
were drinking actively. These were associated with a significantly
lower heart rate and WCC. In the present study, which was
focused on ACLF patients, alcoholism was not associated with
increased 28-day mortality. The reason behind the prescribing
differences of NSBBs in the present study can perhaps be
explained by the fact that patients actively abusing alcohol are
more likely to present for the first time with AD and patients with
previous decompensation have had the opportunity to have been
started on NSBBs during their previous decompensation. How-
ever, why some patients were selected for treatment with NSBBs
is not clear from the CANONIC database. NSBBs were more likely
to be prescribed in patients who had a previous variceal bleed,
which is a group with higher potential risk of death compared
with a population without a previous variceal bleed. Mortality
from variceal bleeding was similar in the cohorts treated with
or without NSBBs. The protection observed in these patients from
the effects of NSBBs is therefore even more noteworthy [28]. In
order to account for these variables a logistic regression model
was developed and the improvement in survival with the use
of NSBBs was independent of these variables.
The occurrence of ACLF in the patients treated with NSBBs
compared with those without was similar but the number of
organ failures reflecting the severity of ACLF was lower in the
NSBB treated patients. In fact, as illustrated in Tables 1 and 2,
the administration of NSBBs was an independent predictor of a
greater likelihood of the patients having ACLF-1 compared with
ACLF-3, which is associated with significantly worse prognosis
[2,4]. As illustrated in Fig. 3, and shown previously, it is clear that
the 28-day mortality of patients with ACLF is predicted by the
CLIF-C ACLF score, which is a combination of the CLIF-C organ
failure score, WCC and age [4]. Fig. 3 reveals that for any given
CLIF-C ACLF score (except at the 2 extreme ends where the mor-
tality rates are very low or very high), the mortality of patients
treated with NSBBs was significantly lower indicating further6 vol. 64 j 574–582 579






Age (yr) 55.5 (12.3) 56.2 (10.6) 0.6222
Male sex 168 (68.3%) 60 (58.3%) 0.0722
Cause of cirrhosis:
  Alcohol alone 135 (56.5%) 63 (63.6%) 0.2245
  HCV alone 33 (13.8%) 15 (15.2%) 0.7473
  HCV + alcohol 26 (10.9%) 5 (5.1%) 0.1010
  Other causes 45 (18.8%) 16 (16.2%) 0.5618
Previous decompensation 183 (77.9%) 70 (70.0%) 0.1251
Ascites 160 (87.9%) 60 (85.7%) 0.6388
Hepatic encephalopathy 84 (46.9%) 38 (55.9%) 0.2086
Gastrointestinal bleeding 53 (29.4%) 24 (35.8%) 0.3361
Spontaneous bacterial 
peritonitis
31 (17.8%) 8 (12.3%) 0.3052
Other 39 (22.3%) 10 (14.9%) 0.2023
Potential precipitating events of ACLF:
At least one PE 140 (59.6%) 65 (64.4%) 0.4099
>1 PE 39 (16.6%) 28 (27.7%) 0.0193
Bacterial infection 73 (29.7%) 37 (35.9%) 0.2519
Gastrointestinal 
hemorrhage
32 (13.0%) 21 (20.4%) 0.0797
Active alcoholism before 
admission
53 (23.1%) 25 (25.3%) 0.6805
Other PE’s 16 (6.8%) 10 (9.9%) 0.3362
Ascites clinically diagnosed 185 (75.8%) 83 (80.6%) 0.3337
Ascites + subrogates of 
ascites
235 (95.6%) 100 (97.1%) 0.7655
Mean arterial pressure 
(mmHg)
79.5 (11.9) 76.6 (14.9) 0.1094
Heart rate (bpm) 81.7 (18.8) 91.4 (20.8) <0.0001
Organ failures:
  Liver 86 (35.0%) 51 (49.5%) 0.0111
  Kidney 119 (48.4%) 59 (57.3%) 0.1289
  Cerebral 47 (19.1%) 34 (33.0%) 0.0050
  Coagulation 70 (28.5%) 38 (36.9%) 0.1199
  Circulation 35 (14.2%) 27 (26.2%) 0.0075
  Lungs 23 (9.4%) 15 (14.6%) 0.1538
 Kidney dysfunction 34 (16.8%) 20 (21.3%) 0.2173
 Mild to moderate hepatic  
encephalopathy
71 (35.2%) 34 (36.2%) 0.9803
CLIF-C  ACLF score 47.1 (8.6) 57.4 (9.6) <0.0001
MELD score 26.5 (7.2) 31.3 (7.2) <0.0001
Laboratory data:
Hematocrit (%) 27 (5) 26 (5) 0.2100
Platelet count (109/L) 91 (71) 86 (68) 0.5484
Serum bilirubin (mg/dl) 10.6 (10.9) 15.2 (12.5) 0.0018
International normalized 
ratio
2.1 (1.0) 2.4 (0.9) 0.0353
Alanine aminotransferase 
(U/L)
33 (19-54) 42 (28-78) 0.0570
Aspartate aminotransferase 
(U/L)
64 (36-107) 103 (55-194) 0.0237
γ-Glutamyltransferase 
(U/L)
72 (37-138) 76 (26-151) 0.4594
Serum creatinine (mg/dl) 1.9 (1.2) 2.4 (1.5) 0.0022
Serum sodium (mmol/L) 135.3 (6.3) 134.6 (6.8) 0.3870
ACLF grade:
  ACLF-1 135 (54.9%) 37 (35.9%)
  ACLF-2 97 (39.4%) 33 (32.0%)
  ACLF-3 14 (5.7%) 33 (32.0%) <0.0001






Data are n (%), mean (standard deviation) or median (Inter-quartile range).
NSBBs, non-selective beta blockers.
Research Articlethat NSBBs provides survival advantage independently in ACLF
patients.
The recent study by Gustot et al. [29] highlights the
dynamic nature of ACLF suggesting that patients can move
rapidly from any grade of ACLF to its resolution from whatever
severity. Conversely, patients with earlier stages can deteriorate
to the more advanced stages. This dynamic nature is best
observed in the first week after hospital admission and the
prognostic value of this observation is reflected in the CLIF-C
ACLF score, where the prediction of outcome improves progres-
sively during the first week. The clinical implication of this
dynamic nature of the ACLF syndrome is the opportunity to
intervene, select patients for liver transplantation and consider
futility of treatment. In ACLF patients of all severities, complete
resolution to no ACLF within 1-week was observed in more
patients treated with NSBBs compared with those not treated,
which did not reach statistical significance. However, signifi-
cantly more of the patient not treated with NSBBs deteriorated
to the more advanced stages.
A potential limitation of this study is that it was not specif-
ically designed to address the role of NSBB, thus lacking data
about compliance and specific reasons why NSBBs were580 Journal of Hepatology 201initiated and stopped but the large prospective study design,
robust data collection and analysis reduces the impact of this
important limitation. The lack of data regarding refractory
ascites classification limits conclusions about the use of NSBBs
but the complete lack of even a signal of a deleterious out-
come, the similarity in the rates of renal dysfunction and over-
all improved survival with NSBBs provides confidence in the
conclusion that NSBBs are likely to be safe even in this
population.
In conclusion, the data presented in this study suggests that
ongoing administration of NSBBs are safe in cirrhotic patients
developing ACLF and its use is associated with improved survival.
The result of this study has not been able to confirm any delete-
rious effect of NSBBs in patients with ascites, SBP or alcoholic
hepatitis. The mechanism it works through is the modulation of
systemic inflammatory responses, which is a key pathophysiolog-
ical derangement observed in ACLF patients but the exact mech-
anisms need to be elucidated. NSBBs provide a safe, cheap and
effective therapy for patients with cirrhosis and until more
prospective data are available, careful thought should be given
to stopping this drug as it reduces mortality if patients go on to
develop ACLF.6 vol. 64 j 574–582
Table 4. Relationship between white cell count, the severity of ACLF and the use of NSBBs. (A) WCC levels (mean and SD) by grade of the first ACLF episode in patients
with and without BBs. (B) WCC levels (mean and SD) by worsening of the first ACLF grade after 3–7 days in patients with and without BBs. (C) WCC levels (mean and SD) by
worsening of the first ACLF grade at the last in-hospital visit in patients with and without BBs.
ACLF grade Patients w/out NSBBs Patients with NSBBs p value between groups
ACLF-1 9.0 (6.4) 7.2 (4.9) 0.0824
ACLF-2 11.9 (6.6) 8.6 (5.4) 0.0042
ACLF-3 12.1 (6.3) 13.5 (8.2) 0.5428
All patients Patients w/out bacterial infections Patients with bacterial infections
ACLF after 3-7 days No NSBBs NSBBs p value No NSBBs NSBBs p value No NSBBs NSBBs p value
Worsened 13.2 (7.0) 7.4 (6.2) 0.0001 11.8 (7.3) 7.1 (3.7) 0.0157 15.4 (6.0) 7.7 (5.1) 0.0038
No change/improved 9.9 (6.4) 8.8 (4.3) 0.1920 9.0 (5.9) 8.2 (6.1) 0.4196 12.2 (7.0) 10.1 (6.4) 0.2043
All patients Patients w/out bacterial infections Patients with bacterial infections
ACLF at the end of the 
hospitalization
No NSBBs NSBBs p value No NSBBs NSBBs p value No NSBBs NSBBs p value
Worsened 13.9 (6.7) 8.2 (5.5) 0.0008 13.0 (7.3) 8.1 (5.8) 0.0325 15.2 (5.7) 8.3 (5.1) 0.0086




NSBBs, non-selective beta blockers.
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